This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A few years back, TIGIT was hailed as the ...
TIGIT is one of the most recent immune checkpoint inhibitors to emerge as a target for drugs that work by modulating its activity in the body. Both antagonists and agonists have been developed against ...
Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Like PD-L1, TIGIT is thought to ...
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to fight cancer, potentially paving the way for new treatments. In a recent ...
Chimeric antigen receptor (CAR) T Cell therapy has emerged as a promising immunotherapeutic approach to treat blood cancers, even leading to long-lasting remission for some advanced cases. The FDA has ...
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been added to ResearchAndMarkets.com's offering. T-cell ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. This is the online edition of ESMO ...
- Arcus will host a conference call today, Wednesday, June 23, 2021 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time to provide an update on its ongoing domvanalimab program HAYWARD, Calif.--(BUSINESS ...
– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC ...
Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response ...
Cellular regulatory mechanisms of TIGIT. TIGIT has the capacity to disrupt the CD226 cis-dimer structure or to competitively bind to CD155, thereby inhibiting cytotoxicity. TIGIT has also been ...
Big Pharma is betting billions on a new class of cancer treatments. The hope is this new target, called TIGIT, can expand the benefits of immunotherapy to more patients. While the first clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results